Skip to main content
OpenTrials
Completed

NCT Number: NCT02320734

Deep Neuromuscular Relaxation in Patients for Thoraco-laparoscopic Esophagectomy

Rationale: Endoscopic (thoraco-laparoscopic) esophageal surgery is a high risk procedure where the use of deep neuromuscular block (NMB) may increase field visibility and anaesthesia conditions. Under these conditions, boluses of muscle relaxants can be given on indication only OR by continuous infusion. We hypothesize that deep NMB by continuous infusion of rocuronium as compared to on demand bolus administration facilitates surgical and anesthesia conditions during thoraco-laparoscopic esophageal resection but higher doses of sugammadex are needed to reverse NMB at the end of surgery.

Objective: Primary objective is to evaluate the use of deep muscle relaxation versus on indication only on surgical and anesthesia conditions in patients for endoscopic esophageal resection. Secondary objectives are to evaluate the (hypothetical) dose of sugammadex needed in both groups in an economical perspective and to compare the intra-operative cardiac and respiratory incidents and post-operative complication rate of both groups.

Study design: a single-center randomized controlled double-blinded intervention study.

Study population: All patients > 18 years to undergo a thoracolaparoscopic esophageal resection.I Intervention: Patients are randomized to receive either continuous infusion of rocuronium 0.6 mg/kg/hr (group 1) or continuous infusion of NaCl 0.9% 0.06 ml/kg/hr (group 2). On demand boluses of Rocuronium 0.3 mg/kg can be given in both groups.

Main study parameters/endpoints: The primary outcome parameter of this study is the SRS during the abdominal phase of thoracolaparoscopic esophageal surgery. Secondary outcomes measured are SRS during the thoracic phase, the number of on demand boluses infused, the dose of Sugammadex needed in both groups to reach a TOF of > 90%, duration of surgery, a cost-analysis, the incidence of intra-operative cardiac and respiratory incidents and the ability of surgeons to estimate which neuromuscular blocking regime was given to the patient.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Academic Medical Center

Amsterdam, North Holland, 1105 AZ, Netherlands

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients, undergoing elective thoraco-laparoscopic esophageal resection (either Ivor Lewis or McKeown variant)
  • Written informed consent

Exclusion criteria

  • pregnancy
  • Known allergies for aminosteroid-type muscle relaxants or sugammadex.
  • Severe kidney dysfunction (GFR < 30), patients on dialysis
  • Liver function disorders
  • Myasthenia Gravis or other (neuro)muscular diseases
  • Patients with carcinomatosis
  • Use of anti-epileptics and lithium or drugs containing Kinin

Treatment and study plan

Rocuronium

Drug

Rocuronium given continuously to reach deep neuromuscular block

Other names: Esmeron

Primary outcomes

  1. Rating of surgical conditions (SRS) during the abdominal phase of the operation.

    Time frame: during operation

Secondary outcomes

  1. Rating of SRS during thoracic phase of the operation.

    Time frame: during operation

  2. Number of on demand boluses infused, indication of on demand bolus administration

    Time frame: during operation

  3. Rating of anesthesia conditions

    Time frame: during operation

    peak and mean respiratory pressure, incidence peak insufflation pressure >35 mmHg. Depth of NBM at the end of surgery. Time until spontaneous breathing, time until extubation. Peroperative cardiac and respiratory incidents, peroperative surgical complications.Tiem to reversal of NMB, % of recurarisation

  4. Costs (euro's) associated with use of Rocuronium, Sugammadex, operation time and length of stay ICU.

    Time frame: during operation and an average of 4 weeks thereafter

    amount of rocuronium used (mg); Dose of sugammadex needed (mg), duration of surgery, hypothetical need for post-operative ventilation if sugammadex would not be available(%).

  5. Number of correct estimates of group randomization by surgeons

    Time frame: directly after operation

    Surgeons will guess in which group the patient was randomized (%) and the reason for this choice will be registrated. Accordingly we can estimate whether the surgeons complaints of inadequate NMB are justified and additionally, the chance of bias affecting main outcome parameter.

Other outcomes

  1. length of stay ICU/PACU

    Time frame: participants will be followed for the duration of hospital stay, an expected average of 4 weeks

  2. need for re-intubation

    Time frame: participants will be followed for the duration of hospital stay, an expected average of 4 weeks

  3. post-operative surgical complications

    Time frame: participants will be followed for the duration of hospital stay, an expected average of 4 weeks

  4. VAS-scores

    Time frame: 24-hours post operation

  5. Abdominal and thoracic insufflation pressures

    Time frame: During operation

Sponsors and collaborators

Lead sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Other

Collaborators

  • Merck Sharp & Dohme LLC

Registry information

Official study title

A Randomized Controlled Double-blinded Trial Comparing the Effect of on Demand vs Deep Neuromuscular Relaxation on Rating of Surgical and Anesthesia Conditions in Patients Undergoing Thoraco-laparoscopic Esophagectomy

Acronym: DEPTH

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Dec 19, 2014
Registry last updated
Sep 19, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.